How many employees does Passage Bio have this year?
Passage Bio has 20 undefined employees this year.
Passage Bio Employees 2024
Passage Bio Employees
20
Ticker
PASG
ISIN
US7027121000
WKN
A2P0EQ
In 2024, Passage Bio employed 20 people, a 0% change from the 20 number of employees in the previous year.
Passage Bio Aktienanalyse
What does Passage Bio do?
Passage Bio Inc is a biopharmaceutical company focused on the treatment of rare genetic diseases. The company is headquartered in Pennsylvania, USA and was founded in 2018. The beginnings of Passage Bio Inc can be traced back to the work of the Penn Medicine Gene Therapy Program, which has been focusing on researching gene therapies for rare diseases for many years. In 2018, the company was finally founded to bring the research results to the market and help patients with rare diseases. Passage Bio's business model is to develop and market gene therapies based on AAV (Adeno-associated viruses). These viruses are injected into the body and are used to transport healthy genes into cells to replace defective or diseased genes. This can restore the production of missing or damaged proteins, which can contribute to symptom relief and disease cure. The company specializes in developing gene therapies for rare, monogenic diseases that are often caused by a single genetic defect. Such diseases are often difficult to treat and have no effective therapies. Therefore, gene therapies can be a promising option to help patients with these diseases. Passage Bio currently has four gene therapy candidates in its pipeline, all focusing on rare neurological diseases. The first candidate, PBGM01, aims to treat GM1 gangliosidosis, a genetic disorder that leads to impairment of the nervous system and often severe impairment of intellectual and physical development. The other candidates focus on treating diseases such as Krabbe disease, frontotemporal dementia, and Niemann-Pick disease type A. Passage Bio has also partnered with Catalent to support the manufacturing and packaging of its gene therapy products. The two companies are working together to develop a scalable production platform for gene therapy manufacturing, which will enable Passage Bio to produce and distribute therapies on a large scale. Overall, Passage Bio has the potential to change the lives of many patients with rare diseases. By developing gene therapies based on AAV technology, the company can create a promising therapy option for patients who currently have no other options available. With a dedicated team of researchers and development specialists, the company is working hard to develop new gene therapies that can contribute to the relief and cure of rare and serious diseases. Passage Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Employees Details
Examining Passage Bio's Employee Base
Passage Bio's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Passage Bio's operational capacity and future potential.
Year-to-Year Comparison
Assessing Passage Bio's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.
Impact on Investments
Passage Bio's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.
Interpreting Employee Trends
Fluctuations in Passage Bio’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.
Frequently Asked Questions about Passage Bio stock
How many employees did Passage Bio have compared to the previous year?
Compared to the previous year, Passage Bio had 0% more employees.
What impact did the number of employees have on the company Passage Bio?
The number of employees has a direct impact on the efficiency and productivity of Passage Bio. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.
What impact did the number of employees have on investors of Passage Bio?
The number of employees can also have an impact on investors of Passage Bio, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.
How does an increase in equity capital of Passage Bio affect the company?
An increase in equity of Passage Bio can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.
How does a reduction in Passage Bio's equity affect the company?
A reduction in equity of Passage Bio can impair its financial stability and decrease its ability to fulfill future investments and obligations.
What are some factors that influence the equity of Passage Bio?
Some factors that can influence the equity of Passage Bio include, among others, revenue development, profit and loss statement, dividend payments, and investments.
Why is the equity of Passage Bio so important for investors?
The equity of Passage Bio is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.
How does the number of employees at Passage Bio influence the company?
The number of employees at Passage Bio can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.
How has the number of employees at Passage Bio evolved in recent years?
In recent years, the number of employees at Passage Bio has changed by 0.
How many employees does Passage Bio currently have?
Passage Bio currently has 20 undefined employees.
Why is the number of employees important for investors of Passage Bio?
The number of employees is important for investors of Passage Bio as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.
What strategic measures can Passage Bio take to change the number of employees?
To change the number of employees, Passage Bio can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.
How much dividend does Passage Bio pay?
Over the past 12 months, Passage Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Passage Bio is expected to pay a dividend of 0 USD.
What is the dividend yield of Passage Bio?
The current dividend yield of Passage Bio is .
When does Passage Bio pay dividends?
Passage Bio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Passage Bio?
Passage Bio paid dividends every year for the past 0 years.
What is the dividend of Passage Bio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Passage Bio located?
Passage Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Passage Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Passage Bio from 10/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.
When did Passage Bio pay the last dividend?
The last dividend was paid out on 10/8/2024.
What was the dividend of Passage Bio in the year 2023?
In the year 2023, Passage Bio distributed 0 USD as dividends.
In which currency does Passage Bio pay out the dividend?
The dividends of Passage Bio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Passage Bio
Our stock analysis for Passage Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Passage Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
